Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „treated“
Suchtreffer
Begriffe & Kennungen
Accofil · 4.8 · Cutaneous vasculitis Cutaneous vasculitis has been reported in patients treated with Filgrastim. The mechanism
Eintrag öffnenAccofil · 4.8 · Cutaneous vasculitis Cutaneous vasculitis has been reported in patients treated with Filgrastim. The mechanism
Eintrag öffnenAccofil · 4.8 · Cutaneous vasculitis Cutaneous vasculitis has been reported in patients treated with Filgrastim. The mechanism
Eintrag öffnenAdcetris · 4.8 · 14 The safety data in patients retreated with ADCETRIS (SGN35-006, see section 5.1) were consistent with those
Eintrag öffnenAdcetris · 4.8 · In patients with relapsed or refractory HL or sALCL who were retreated with ADCETRIS (SGN35-006), the majority
Eintrag öffnenAdcetris · 4.8 · In the studies of ADCETRIS as combination therapy in 662 patients with previously untreated advanced HL (C2500
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.8 · 10 were treated with placebo, for 24 weeks. The most common AEs, occurring in ≥ 2 patients treated with tadala
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.8 · 27 weight cohort, ≥ 25 kg to < 40 kg) or 40 mg (heavy-weight cohort, ≥ 40 kg), and 18 patients were treated wi
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.8 · A total of 51 paediatric patients aged from 2.5 to 17 years with PAH were treated with tadalafil in clinical t
Eintrag öffnenAdcirca (previously Tadalafil Lilly) · 4.8 · A total of 51 paediatric patients aged from 2.5 to 17 years with PAH were treated with tadalafil in clinical t
Eintrag öffnenAdtralza · 4.8 · Eczema herpeticum Eczema herpeticum was reported in 0.3% of the subjects treated with tralokinumab and in 1.5%
Eintrag öffnenAdtralza · 4.8 · Eosinophilia Adverse reactions of eosinophilia were reported in 1.3% of patients treated with tralokinumab and
Eintrag öffnenAdtralza · 4.8 · Keratitis was reported in 0.5% of subjects treated with tralokinumab during the initial treatment period. Of t
Eintrag öffnenAdvate · 4.8 · Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with fact
Eintrag öffnenAdvate · 4.8 · Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with fact
Eintrag öffnenAdvate · 4.8 · Of the 229 treated patients who were assessed for antibodies to Chinese hamster ovary (CHO) cell protein, 3 sh
Eintrag öffnenAdvate · 4.8 · Of the 229 treated patients who were assessed for antibodies to Chinese hamster ovary (CHO) cell protein, 3 sh
Eintrag öffnenAdynovi · 4.8 · 6 previously-untreated patients (PUPs), who received at least one dose of ADYNOVI in 7 completed multi-centre,
Eintrag öffnenAdynovi · 4.8 · Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with fact
Eintrag öffnenAdynovi · 4.8 · Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with fact
Eintrag öffnen